143 related articles for article (PubMed ID: 35150749)
21. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16).
Chen LS; Liao CS; Chang SH; Lai HC; Chen TH
J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564
[TBL] [Abstract][Full Text] [Related]
22. Would initiating colorectal cancer screening from age of 45 be cost-effective in Germany? An individual-level simulation analysis.
Lwin MW; Cheng CY; Calderazzo S; Schramm C; Schlander M
Front Public Health; 2024; 12():1307427. PubMed ID: 38454984
[TBL] [Abstract][Full Text] [Related]
23. Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.
Westwood M; Corro Ramos I; Lang S; Luyendijk M; Zaim R; Stirk L; Al M; Armstrong N; Kleijnen J
Health Technol Assess; 2017 May; 21(33):1-234. PubMed ID: 28643629
[TBL] [Abstract][Full Text] [Related]
24. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
Ladabaum U; Mannalithara A
Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
[TBL] [Abstract][Full Text] [Related]
25. Piloting gender-oriented colorectal cancer screening with a faecal immunochemical test: population-based registry study from Finland.
Sarkeala T; Färkkilä M; Anttila A; Hyöty M; Kairaluoma M; Rautio T; Voutilainen M; Helander S; Jäntti M; Lehtinen M; Patrikka L; Malila N; Heinävaara S
BMJ Open; 2021 Feb; 11(2):e046667. PubMed ID: 33558363
[TBL] [Abstract][Full Text] [Related]
26. Gender-specific cut-offs in colorectal cancer screening with FIT: Increased compliance and equal positivity rate.
Blom J; Löwbeer C; Elfström KM; Sventelius M; Öhman D; Saraste D; Törnberg S
J Med Screen; 2019 Jun; 26(2):92-97. PubMed ID: 30336730
[TBL] [Abstract][Full Text] [Related]
27. Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer.
Gini A; Zauber AG; Cenin DR; Omidvari AH; Hempstead SE; Fink AK; Lowenfels AB; Lansdorp-Vogelaar I
Gastroenterology; 2018 Feb; 154(3):556-567.e18. PubMed ID: 29102616
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness of Earlier or More Intensive Colorectal Cancer Screening in Overweight and Obese Patients.
Yeoh A; Mannalithara A; Ladabaum U
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):507-519. PubMed ID: 35940514
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and cost-effectiveness of fecal immunochemical test versus colonoscopy in colorectal cancer screening: a systematic review and meta-analysis.
Zhong GC; Sun WP; Wan L; Hu JJ; Hao FB
Gastrointest Endosc; 2020 Mar; 91(3):684-697.e15. PubMed ID: 31790657
[TBL] [Abstract][Full Text] [Related]
30. Adding family history to faecal immunochemical testing increases the detection of advanced neoplasia in a colorectal cancer screening programme.
Kallenberg FG; Vleugels JL; de Wijkerslooth TR; Stegeman I; Stoop EM; van Leerdam ME; Kuipers EJ; Bossuyt PM; Dekker E
Aliment Pharmacol Ther; 2016 Jul; 44(1):88-96. PubMed ID: 27170502
[TBL] [Abstract][Full Text] [Related]
31. The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline.
Peterse EFP; Meester RGS; Siegel RL; Chen JC; Dwyer A; Ahnen DJ; Smith RA; Zauber AG; Lansdorp-Vogelaar I
Cancer; 2018 Jul; 124(14):2964-2973. PubMed ID: 29846933
[TBL] [Abstract][Full Text] [Related]
32. Fecal immunochemical test in colorectal cancer screening: Colonoscopy findings by different cut-off levels.
Ribbing Wilén H; Blom J; Höijer J; Hultcrantz R
J Gastroenterol Hepatol; 2019 Jan; 34(1):103-112. PubMed ID: 29968937
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening.
Wilschut JA; Hol L; Dekker E; Jansen JB; Van Leerdam ME; Lansdorp-Vogelaar I; Kuipers EJ; Habbema JD; Van Ballegooijen M
Gastroenterology; 2011 Nov; 141(5):1648-55.e1. PubMed ID: 21784045
[TBL] [Abstract][Full Text] [Related]
34. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness, benefit harm and cost effectiveness of colorectal cancer screening in Austria.
Jahn B; Sroczynski G; Bundo M; Mühlberger N; Puntscher S; Todorovic J; Rochau U; Oberaigner W; Koffijberg H; Fischer T; Schiller-Fruehwirth I; Öfner D; Renner F; Jonas M; Hackl M; Ferlitsch M; Siebert U;
BMC Gastroenterol; 2019 Dec; 19(1):209. PubMed ID: 31805871
[TBL] [Abstract][Full Text] [Related]
36. The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based On Phenotypic and Genetic Risk: A Health Economic Analysis.
Thomas C; Mandrik O; Saunders CL; Thompson D; Whyte S; Griffin S; Usher-Smith JA
Cancer Prev Res (Phila); 2021 Aug; 14(8):811-822. PubMed ID: 34039685
[TBL] [Abstract][Full Text] [Related]
37. Colorectal cancer screening at age 45 years in Israel: Cost-effectiveness and global implications.
Half EE; Levi Z; Mannalithara A; Leshno M; Ben-Aharon I; Abu-Freha N; Silverman B; Ladabaum U
Cancer; 2024 Mar; 130(6):901-912. PubMed ID: 38180788
[TBL] [Abstract][Full Text] [Related]
38. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies.
Sharaf RN; Ladabaum U
Am J Gastroenterol; 2013 Jan; 108(1):120-32. PubMed ID: 23247579
[TBL] [Abstract][Full Text] [Related]
39. Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening.
Goede SL; Rabeneck L; van Ballegooijen M; Zauber AG; Paszat LF; Hoch JS; Yong JH; Kroep S; Tinmouth J; Lansdorp-Vogelaar I
PLoS One; 2017; 12(3):e0172864. PubMed ID: 28296927
[TBL] [Abstract][Full Text] [Related]
40. The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cut-off level on yield of screening.
Kooyker AI; Toes-Zoutendijk E; Opstal-van Winden AWJ; Spaander MCW; Buskermolen M; van Vuuren HJ; Kuipers EJ; van Kemenade FJ; Ramakers C; Thomeer MGJ; Dekker E; Nagtegaal ID; de Koning HJ; van Leerdam ME; Lansdorp-Vogelaar I
Int J Cancer; 2020 Aug; 147(4):1098-1106. PubMed ID: 31853977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
